When Amanda, 28, found out that she was pregnant with her second child, she was in the middle of the COVID-19 pandemic and struggling with opioid use disorder. “I was pretty heavy into my drug use,” said Amanda, whose last name is being withheld due to patient confidentiality. “I had given up hope and was figuring out a way to use drugs and get away with the consequences. But it doesn’t work like that.”
Now, however, Amanda is feeling “really good.” That’s because she is in a clinical trial for pregnant women run by the Yale School of Medicine, through which she receives medication-assisted treatment (MAT) for her opioid use disorder (OUD). Amanda’s OB-GYN is among a group of physicians at 12 clinics in Connecticut and Massachusetts who are training with Yale to offer OB-GYN care and treatment for substance use disorder under one roof to pregnant patients.
William Evans grew up in Brookfield, a high school tennis player from a family with an Ivy League pedigree. By the time he was working at his first job after college, he was addicted to opioids, spending $25,000 in less than a year and driving to Philadelphia twice a week to buy drugs on the street. Now 37, Evans hasn’t used illegal drugs since 2006. He is married and has a 3-year-old daughter, a home in Trumbull, and a sales job at a software company. He attributes his sobriety to counseling and medication to treat his addiction.
Combining medication with other forms of therapy can help people with opioid addition avoid relapse by calming cravings and managing the symptoms of withdrawal. Less than half of the privately drug addiction programs nationally offer medication-assisted treatment (MAT); and even in those programs, only one-third of patients receive MAT, according to the National Institute of Drug Abuse. In Connecticut, there are about 40 Medicaid providers that prescribe medication for treatment. In our podcast, sponsored by Wheeler Clinic, Dr. Robert Grillo discusses medication-assisted treatment for opioid addiction. Increasing access to MAT is important given the extreme danger associated with relapse, says Dr. Robert Grillo, medical director for psychiatry at Wheeler Clinic.